Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054

J Immunother Cancer. 2022 Jan;10(1):e004272. doi: 10.1136/jitc-2021-004272.
No abstract available

Keywords: adjuvants; autoimmunity; immunologic; immunotherapy; melanoma.

Publication types

  • Letter
  • Comment

MeSH terms

  • Adjuvants, Immunologic
  • Humans
  • Melanoma*
  • Skin Neoplasms*

Substances

  • Adjuvants, Immunologic